ARTICLE | Company News
Savient metabolic news
November 1, 2010 7:00 AM UTC
Savient said it was unable to sell itself at this time. In May, Savient said it would sell the company following FDA's approval of gout drug Krystexxa pegloticase, which occurred in September. Savien...